
Ipamorelin is a synthetic pentapeptide and selective growth-hormone secretagogue-receptor (GHS-R) agonist. Supplied as a lyophilized powder, it is intended for in-vitro laboratory research into ghrelin-receptor signaling and growth-hormone release pathways.
Ipamorelin is studied in the preclinical literature as a selective GH secretagogue acting on the ghrelin / GHS-R pathway, with minimal reported effect on cortisol or prolactin in laboratory models.
Every lot is independently tested for identity and purity by SideChain Analytics (HPLC-MS/MS), and a Certificate of Analysis is available for each batch. Produced and shipped from within Canada.
Available exclusively for in-vitro laboratory research. Not a drug, natural health product, or food; not for human or veterinary use, and not evaluated for diagnostic or therapeutic application. Researchers are responsible for compliance with all applicable regulations.
Reported in preclinical, in-vitro literature in the following research areas:
• GHS-R / ghrelin-receptor signaling
• GH-release pathway research
• Receptor-selectivity models
• Peptide secretagogue pharmacology
These are areas of laboratory investigation only. No physiological, clinical, or health outcome is claimed or implied for any use of this compound.
Ipamorelin has been reported to act as a selective agonist of the growth-hormone secretagogue receptor (GHS-R1a), stimulating GH-release signaling in preclinical models.